Br. J. Cancer

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.

M Javle, J Yu, C Garrett, A Pande, B Kuvshinoff, A Litwin, J Phelan, J Gibbs, R Iyer

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).

-Adult
-Aged
-Aged, 80 and over
-Antibodies, Monoclonal (-administration & dosage)
-Antineoplastic Combined Chemotherapy Protocols (+therapeutic use)
-Deoxycytidine (-administration & dosage; -analogs & derivatives)
-Female
-Fluorouracil (-administration & dosage; -analogs & derivatives)
-Humans
-Liver Neoplasms (+drug therapy; -secondary)
-Lung Neoplasms (+drug therapy; -secondary)
-Lymphatic Metastasis
-Male
-Middle Aged
-Pancreatic Neoplasms (+drug therapy; -pathology)
-Prognosis
-Survival Rate
-Treatment Outcome

pii:6605099
doi:10.1038/sj.bjc.6605099
pubmed:19491904
pmc:PMC2714236

